A proposed class action has been filed accusing AbbVie, Amgen, Samsung Bioepis, Mylan, Mylan, Sandoz, Fresenius Kabi, Pfizer, and Momenta Pharmaceuticals of unlawfully restraining competition in the market for the drug Humira and its biosimilar competitors. The complaint claims AbbVie has created a “patent thicket” - securing over 100 patents designed solely to insulate Humira from competition - and entered into illegal agreements with the remaining companies to delay biosimilar entry in the US until at least 2023.
To add details to this Case File regarding legal or economic representatives, please contact editors@mlex.com.